MUNDELEIN, Ill., Oct. 15 /PRNewswire/ -- Bio-logic Systems Corp.
(Nasdaq: BLSC), a designer and marketer of computerized medical electro-
diagnostic equipment, today announced that it has received ISO 9001 and
European Medical Device Directive (MDD) certifications for its full Quality
Management System.  The ISO 9001 certification signifies that the company
conforms with regulatory requirements for the design, manufacturing,
distribution and servicing of the company's electroencephalograph systems
(EEG) and evoked response (EP) systems.  The MDD award acknowledges that these
systems meet the rigid safety requirements for medical devices in Europe.  The
European Communities require certification to the MDD if a company wants to
sell there.
    "This is a significant milestone for Bio-logic," said Dr. Gabriel Raviv,
president and chief executive officer.  "We worked hard to achieve ISO 9001
and MDD certification, which is the European equivalent to FDA approval in the
United States, allowing us to continue to aggressively market our EEG and EP
systems in the 18 European Union countries.  With the achievement of ISO 9001,
we have strengthened our competitive position by providing our customers with
the confidence of purchasing products and services from us that meet
international standards for consistent quality systems."
    Bio-logic Systems Corp., headquartered in Mundelein, Ill., designs,
develops, assembles and markets computer-based electro-diagnostic systems for
use by hospitals, clinics, universities and physicians.  The systems conduct
tests that are typically used by medical practitioners to aid in the diagnosis
of certain neurological, psychiatric and sensory disorders, psychological and
learning disorders, brain disorders and tumors.
    Except for descriptions of historical facts, this release contains
forward-looking statements that involve known and unknown risks, which may
cause the company's actual results in the future to differ materially from
those currently anticipated.  These risks include, among others, fluctuations
in sales and operating results; risk associated with international operations
including monetary crisis; regulatory, competitive and contractual risks; the
effects of economic conditions; and the availability of capital to finance
planned growth, as well as other risks detailed from time to time in the
company's filings with the Securities and Exchange Commission.

Link to this page: